Skip to main content

Sjögren Syndrome clinical trials at UCLA

1 research study open to eligible people

Showing trials for
  • Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

    open to eligible people ages 18 years and up

    A randomized, double-blind, placebo controlled, 2-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjogren's syndrome (NEPTUNUS-1)

    Van Nuys, California and other locations

Last updated: